文献速递消化道肿瘤与早癌

姜黄素治疗家族性腺瘤性息肉病患者肠道腺瘤的疗效与安全性

Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
PubMed 文献 · Gastroenterology · 2018-05-23

这项双盲随机试验纳入44例家族性腺瘤性息肉病患者,随机分入姜黄素组(口服100%纯姜黄素1,500 mg,每日两次)或安慰剂组,治疗12个月。治疗12周后,姜黄素组与安慰剂组的息肉平均数量与平均大小均无显著差异,不良事件少见且组间无显著差异。

要点

  • 姜黄素3,000 mg/日与安慰剂相比,治疗12周后息肉平均数量无显著差异。
  • 姜黄素组与安慰剂组的息肉平均大小无显著差异。
  • 不良事件少见,两组间无显著差异。

核心结论

  • 在家族性腺瘤性息肉病患者的双盲随机试验中,姜黄素3,000 mg/日与安慰剂治疗12周后,下消化道腺瘤的平均数量或大小均无差异。

研究设计与样本

  • 双盲随机试验,纳入44例家族性腺瘤性息肉病患者(18-85岁),按1:1随机分入姜黄素组(100%纯姜黄素1,500 mg口服,每日两次)或安慰剂组,治疗12个月。
  • 患者来自波多黎各或美国,入组时间为2011年9月至2016年11月,未行结肠切除术或已行结肠切除术伴回肠直肠吻合术或回肠肛门储袋术,且至少有5个肠道腺瘤性息肉。
  • 主要结局为治疗12个月时或退出研究时姜黄素组与安慰剂组的息肉数量,按意向性治疗原则分析。

主要发现

  • 治疗1年后,姜黄素组平均依从率为83%,安慰剂组为91%。
  • 治疗12周后,安慰剂组息肉平均数量为18.6(95%CI 9.3-27.8),姜黄素组为22.6(95%CI 12.1-33.1),组间无显著差异(P = .58)。
  • 姜黄素组息肉平均大小为2.3 mm(95%CI 1.8-2.8),安慰剂组为2.1 mm(95%CI 1.5-2.7),组间无显著差异(P = .76)。
  • 不良事件少见,组间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blinded randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. METHODS: This study included 44 patients with familial adenomatous polyposis (18-85 years old) who had not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches, had at least 5 intestinal adenomatous polyps, and had enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100% pure curcumin (1,500 mg orally, twice per day) or identical-appearing placebo capsules for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. RESULTS: After 1 year of treatment, the average rate of compliance was 83% in the curcumin group and 91% in the placebo group. After 12 weeks, there was no significant difference in the mean number of polyps between the placebo group (18.6; 95% CI, 9.3-27.8) and the curcumin group (22.6; 95% CI, 12.1-33.1; P = .58). We found no significant difference in mean polyp size between the curcumin group (2.3 mm; 95% CI, 1.8-2.8) and the placebo group (2.1 mm; 95% CI, 1.5-2.7; P = .76). Adverse events were few, with no significant differences between groups. CONCLUSIONS: In a double-blinded randomized trial of patients with familial adenomatous polyposis, we found no difference in the mean number or size of lower intestinal tract adenomas between patients given curcumin 3,000 mg/day and those given placebo for 12 weeks. Clinicaltrials.gov ID NCT00641147.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology. 2018. PMID: 29802852. doi:10.1053/j.gastro.2018.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。